Long-term vascular access for infants with moderate to severe osteogenesis imperfecta
link.springer.com shows its articles on its own site.
Read the article on link.springer.com ↗Article · Nov 2021 · 1 min read
In brief
In brief
Retrospective study of 17 pediatric OI patients demonstrates that port-a-cath placement is safe and effective for long-term bisphosphonate delivery, with devices remaining in place for median 53.5 months and low complication rates. Findings support early port placement to prevent iatrogenic fractures from repeated IV access attempts in fragile infants.
Written by the GCMD Library team from the article.
Abstract
Purpose
Osteogenesis imperfecta (OI) is a genetic disorder that causes skeletal fragility. For the most fragile infants and young children with OI, intravenous (IV) bisphosphonate administration is essential, but IV access attempts often cause fractures. Port-a-caths help prevent these events, but some surgeons are hesitant to insert these devices in these infants due to lack of data on their safety.
Methods
Retrospective study of pediatric patients with OI who underwent port-a-cath placement from 1999 to 2018; incidence of complications such as infection and thrombosis and need for reoperation or replacement are described.
Results
Port-a-caths were placed in 17 patients with OI (median age, 8 mos [5–23 mos]; median weight, 5.8 kg [3.96–9.08 kg]) and remained in place for a median of 53.5 mos (10–127 mos). One port-a-cath was replaced because of thrombosis. Two port-a-caths were removed because of malfunction, one for skin erosion, and one for infection. In these five cases, replacement was not needed because patients could safely tolerate IV access. Two patients have their port-a-cath in place and the remaining ten patients had theirs removed electively as it was no longer needed.
Conclusion
Port-a-cath placement in pediatric patients with OI is safe and efficacious for durable central access, enabling reliable IV bisphosphonate delivery and reducing iatrogenic trauma.